Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Translational Oncology
Capmatinib-induced Resistant Hs 746T In Vivo Model

ADC-related Platform for Preclinical Research
(1)  ADC-related in vitro assays
  • Target validation and antibody binding assay
  • Antibody internalization assay
  • Cell viability assay
  • Bystander killing assay
  • ADCC and ADCP assay

(2)  WuXi AppTec ADC-related in vivo models
  • CDX and PDX models covering multiple hot targets (HER2, CLDN18.2, CD30, CD33, BCMA, Trop-2, CD79b, Nectin-4, etc.)
Targeted Oncology
HDACs-related In Vivo Models


(2)  Mino lymphoma CDX model, tested with ACY-1215 and Ibrutinib

(3)  MV4-11 leukemia CDX model, tested with ACY-1215 and Panobinostat

KRAS G12C Mutation Related In Vivo Models

(1)  KRAS G12C mutation related CDX models
  • AMG 510 3D CTG validation across 13 cancer cell lines with KRAS G12C mutation
  • NCI-H1373, HCC44, NCI-H358, NCI-H2030, NCI-H2122, NCI-H23, and SW1573 lung cancer CDX models with KRAS G12C mutation, tested with AMG 510 and ARS-1620
  • MIA PaCa-2 pancreatic cancer CDX model with KRAS G12C mutation, tested with AMG 510 and ARS-1620
  • SW1463 and SW837 colorectal cancer CDX models with KRAS G12C mutation, tested with AMG 510
  • SW756 cervical cancer CDX model with KRAS G12C mutation, tested with AMG 510

(2)  PDX models with KRAS G12C mutation, tested with AMG 510
  • 11 lung cancer PDX models
  • 4 colorectal cancer PDX models
  • 1 gastric cancer PDX model
We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
 
Best regards,
WuXi AppTec OncoWuXi Team